BiotechTube
Julius Clinical

Julius Clinical

Zeist, Netherlands· Est.
juliusclinical.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Julius Clinical is a global, full-service CRO with deep therapeutic expertise in CNS, cardio-renal-metabolic, and infectious diseases. Its recent merger with P95 has created a 500+ person organization with integrated capabilities spanning clinical development and real-world evidence (RWE) generation. The company leverages its scientific networks and operational focus to deliver high-quality data and patient recruitment for complex trials in its core therapeutic areas.

Neurological diseasesCardio-Metabolic and Renal diseasesInfectious diseases & Vaccines

Technology Platform

Integrated CRO model combining scientific leadership/therapeutic expertise, dedicated site networks, and operational delivery. Enhanced post-merger with Real-World Evidence (RWE) and epidemiology capabilities from P95.

Funding History

1
UndisclosedUndisclosed

Opportunities

The merger with P95 creates a leading, integrated CRO offering both clinical trial and real-world evidence services, capturing more of the drug development value chain.
Growing R&D investment in complex neurological, metabolic, and infectious diseases aligns perfectly with the company's deep therapeutic specialization, driving demand for its services.

Risk Factors

Key risks include the operational and cultural challenges of integrating the recent merger with P95.
The company also faces intense competition in the CRO market and is exposed to macroeconomic fluctuations that could reduce biopharma R&D spending and outsourcing budgets.

Competitive Landscape

Julius Clinical competes in the global CRO market against large, full-service players (e.g., IQVIA, ICON, Parexel) and smaller niche specialists. Its differentiation is its focused therapeutic expertise in three complex areas and its integrated real-world evidence capabilities post-merger, positioning it as a scientifically-led, mid-sized alternative.

More companies in Digital Health & Biotech SaaS →More companies in Netherlands →